Here’s a round-up of the stories thus far: Reuters: FDA bans imports from Sun Pharma plant in India crackdown The U.S. Food and Drug Administration (FDA) has banned imports from Indian generic drugmaker Sun Pharmaceutical Industries Ltd’s plant at Karkhadi in the western state of Gujarat, in the latest quality blow for India’s drug sector. …
Sun Pharmaceutical Industries Ltd announced that one of its subsidiaries has received final approval from US FDA for its Abbreviated New Drug Application (ANDA) for generic version of Gleevec , Imatinib Mesylate tablets 100mg and 400mg Imatinib Mesylate tablets,
Chennai: Drug major Sun Pharmaceutical Industries Ltd on Monday announced the launch of ready-to-administer cancer drug Gemcitabine InfuSMART in Europe. In a statement, the company said InfuSMART is a technology in which oncology/cancer products were developed in a ready-to-administer bag. "Until now, compounding of oncology products was done at compounding centres or compounded in hospi.. Read More
Sun Pharmaceutical Industries Ltd’s southward journey continues for yet another trading session. The scrip is currently trading 1.3% lower at Rs. 709.15 on BSE, which is a 16-month low level. - See more at: http://ways2capital-equitytips.blogspot.in/2015/11/sun-pharma-falls-13-pays-rs-500-cr.html#sthash.7RMIbaax.dpuf
Sun Pharmaceuticals Industries Limited has announced that Sun Pharmaceutical Industries Ltd, along with its subsidiary ( Sun Pharma) has entered into a settlement agreement with Acorda Therapeutics, Inc. - See more at: http://ways2capital-review.blogspot.in/2015/10/sun-pharma-enters-into-agreement-with.html#sthash.Bqbs2zdI.dpuf
Sun Pharmaceutical Industries Ltd. has recalled 68,000 bottles of the antidepressant Effexor in the U.S., in the second recall of the drug this year, the U.S. Food and Drug Administration said http://online.wsj.com/articles/sun-pharma-recalls-effexor-in-u-s-1416297616?mod=WSJ_LatestHeadlines
Sun Pharmaceuticals Industries Ltd is currently trading at Rs. 913, up by 1.7% from its previous closing of Rs. 898.2 on the BSE. - See more at: http://ways2capital-review.blogspot.in/2015/10/sun-pharma-up-17-ranbaxy.html#sthash.G7MF6dF5.dpuf
Sun Pharmaceutical Industries Ltd posted a net profit of Rs. 17136.90 million for the quarter ended March 31, 2016 where as the same was at Rs. 8892.40 - See more at: http://ways2capital-equitytips.blogspot.in/2016/05/sun-pharma-q4-net-profit-at-rs1713690-mn.html#sthash.V5x4pKck.dpuf
Sun Pharma announces USFDA approval for generic Namenda® tablets Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE:SUNPHARMA, BSE: 524715) announced that USFDA has granted its subsidiary an approval for its Abbreviated New Drug Application (ANDA) to market a generic version of Forest Laboratories, Inc.’s Namenda 5 mg and 10 mg tablets.
Shares of Sun Pharmaceutical Industries Ltd are currently trading 1.50% higher at Rs. 770.35 on BSE after it was reported by a financial daily that the company will raise Rs. 1,000 crore from the domestic bond market via its arm Sun Laboratories.
Sun Pharmaceuticals Industries Ltd is currently trading at Rs. 849, up by 8.6 points or 1.02% from its previous closing of Rs. 839.7 - See more at: http://ways2capital-equitytips.blogspot.in/2015/09/sun-pharmaceutical-may-divest.html#sthash.CPXETRiL.dpuf
AstraZeneca Pharma India and Sun Pharmaceutical Industries today said they have entered into a distribution services agreement for AstraZeneca’s brand Axcer, a new brand of ticagrelor, in India. - See more at: http://ways2capital-equitytips.blogspot.in/2015/06/sun-pharma-astrazeneca-in-distribution.html#sthash.Wg2ewbNP.dpuf
Lupin Ltd is looking for acquisitions in Japan to maintain its lead in a bid to counter the threat from the entry of Sun Pharmaceutical Industries in that market, reports a business daily. The Japanese drug market is No.2 in the world estimated at US$73 billion.
Shares of Sun Pharmaceuticals Industries Ltd are currently trading 2.19% lower at Rs. 742.15 on BSE despite the company announcing research collaborations with two world-class universities in the area of neurological diseases. - See more at: http://ways2capital-equitytips.blogspot.in/2015/12/sun-pharma-inks-research-pact-with.html#sthash.F2CcJvlm.dpuf
Pharma major Dr Reddy’s Laboratories consolidated net profit plunged 86 per cent at Rs 74.6 crore in the fourth quarter ended March 31, 2016, - See more at: http://ways2capital-equitytips.blogspot.in/2016/05/dr-reddys-q4-net-dives-86-on-venezuelan.html#sthash.5pYCNthR.dpuf